New York TimesLean L·
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
Read at New York Times →
Business · 2 sources covering this
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
Coverage spectrum
2 L · 0 C · 0 R
How 2 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/6bd74ba67912d426d908d304a0f29c29b9850cb3" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer"></iframe>
